Abstract Polymyalgia rheumatica (PMR)
Introduction
Polymyalgia rheumatica (PMR) is an inflammatory condition of unknown etiology commonly found in the elderly and is often associated with impaired quality of life of these patients [1] . The diagnosis of PMR is mainly based on clinical features such as aches and stiffness in the cervical region, shoulder, and pelvic girdles. There is yet no specific serological marker for this condition. A recent prospective study suggested that PMR is a heterogeneous condition with variable responsiveness to corticosteroid treatment [1] . There is still inconsistency with regard to the guideline on diagnosis, management, and disease response measures in this condition [2] . A number of diagnostic criteria have been proposed to classify PMR [3] [4] [5] , and the criteria proposed by Bird et al. [3] have been more widely used because of their higher sensitivity [6] . The diagnosis of PMR is regarded as definite if the patient fulfills three or more of the criteria including age >65 years, time from onset of symptoms to full-blown disease of less than 2 weeks, bilateral shoulder pain or stiffness, bilateral upper arm tenderness, stiffness >1 h, depression and/or weight loss, and erythrocyte sedimentation rate (ESR) >40 mm/h at onset. Together with a positive response to corticosteroid therapy, the sensitivity of this diagnostic criteria has been reported to be as high as 99.5% [6] .
However, a number of rheumatic conditions including late onset rheumatoid arthritis (RA) [7] , calcium pyrophosphate deposition disease, inflammatory myositis [8] , and fibromyalgia [9] may mimic PMR as they show similar clinical features but carry different prognosis. Seventy-three percent of a large cohort of 100 PMR patients have been reported to develop cranial symptoms related to ischemic events of giant cell arteritis after a median of 3 weeks and among these 16.4% of patients resulted in permanent visual loss [10] . Furthermore, 6-17% of PMR patients have been found to evolve into RA subsequently [7] . Anticyclic citrullinated peptide (CCP) antibodies that have recently been found to be a specific marker for RA [11] have been suggested to be clinically useful in the prediction of PMR patients who subsequently develop into RA [12, 13] . Our study aimed to compare the clinical characteristics of a Chinese cohort of PMR patients to a Caucasian series and to examine the frequency of anti-CCP antibodies in patients with and without subsequent evolvement into RA.
Methodology
This study has been approved by the ethics committee of the local institutional review board. All patients diagnosed to have PMR by trained rheumatologists at a university affiliated hospital and a large regional public hospital in Hong Kong during 1997-2008 were identified through the clinical data analysis and reporting system (International Classification of Diseases (ICD), i.e., ICD 9 Code 725), and their medical records were retrieved for analysis. Demographic data, clinical features, treatment regimen and response as well as laboratory investigations including ESR, rheumatoid factor (RF) and anti-CCP antibodies at disease onset were recorded. The clinical characteristics of these patients were compared with Caucasian series reported according to the criteria of Bird et al. [3] .
Measurement of RF and anti-CCP antibodies RF was performed by latex-enhanced immunonephelometry (BN ProSpec, Dade Behring, Germany) and was considered positive at ≥15 IU/ml. Anti-CCP antibodies were measured by a second-generation anti-CCP enzyme-linked immunosorbent assay (Inova Diagnostic Inc., San Diego, CA, USA) according to the manufacturer's instructions. The cutoff value for positive reaction was set at 20 arbitrary units (AU) as suggested by the manufacturer. The intra-assay variation of the assay was 3.5% with a high-level serum (175 AU) and 6% with a "low-level serum" (21 AU), and interassay variation was 6% for both sera. For patients who presented before the anti-CCP antibody assay was introduced into the hospital serology laboratory in early 2005, the earliest available serum samples after onset of presentation were retrieved and tested.
Statistical analysis
Statistical analysis was performed by SPSS 16.0 software (Chicago, IL, USA). Data were presented as mean± standard deviation (SD) unless otherwise stated. Chisquare test or Fisher's exact test was performed for categorical variables. Mann-Whitney U test was used for comparison on continuous data between groups. KaplanMeier survival curve and log-rank test were used to compare the frequency of RF and anti-CCP antibody among patients who had and had not evolved into RA subsequently.
Results

Presenting features of PMR
Forty-four (31 females and 13 males) patients of southern Chinese origin were identified from these two large regional hospitals during 1997-2008. The mean±SD age of these patients was 75.8±9.6 years with a mean duration of follow-up of 4.9±2.9 years. Table 1 shows a summary of the clinical features of these patients compared to those reported in a Caucasian series [6] . There was similar proportion of Chinese patients (75.0%) aged over 65 years Predictive role of RF and anti-CCP antibodies in PMR patients who evolved into RA RF was checked in all patients and anti-CCP antibodies in 21 patients. Among the 12 patients who had evolved into RA, 66.7% were RF positive and 60% were anti-CCP positive. RF and anti-CCP antibodies were present in only 9.4% and 6.2% for those who had not evolved into RA (n=32) for the period observed ( Table 2 ). The positive and negative predictive values for RF in the development of RA were 72.7% and 87.9%, respectively, while those for anti-CCP antibodies were 75.0% and 88.2%, respectively. Figure 1 shows the Kaplan-Meier survival curve with evolvement into RA among PMR patients who were seropositive for RF (Fig. 1a) or anti-CCP antibodies (Fig. 1b) compared to those who were not. Patients who had positive serum RF (p<0.01) and anti-CCP antibodies (p=0.02) were more likely to develop RA during the period of observation.
Discussion
Our study showed that Chinese patients with PMR presented with similar features as the Caucasian counterpart including age at onset, bilateral shoulder pain or stiffness, constitutional symptoms, and ESR >40 mm/h. However, our patients were found to complain less of bilateral upper arm tenderness and generalized stiffness. Our patients also had longer duration of symptoms before seeking medical help. This may be due to the lack of awareness of an underlying rheumatic disease as nonspecific musculoskeletal rheumatism are frequent complaints in the elderly or that Chinese patients may demonstrate a different health care seeking behavior. Indeed, cultural and social influences have been demonstrated to affect the experience and adjustment to pain among subjects of different racial or ethnic groups [15] .
Our study showed that 27.3% of Chinese patients with initial diagnosis of PMR subsequently evolved into RA after a median of 2 months (range 1-24 months) since disease onset. This frequency was higher than the Western cohort where 6-17% of patients have been reported to develop into RA after a period of 3 to 5 years [12] . This may be related to the small sample size of our study and may also be explained by the more subjective items in the criteria of Bird et al. that lead to variations in different populations. Furthermore, PMR patients who had milder symptoms and those who readily respond to NSAIDs alone may have been managed at the primary care instead of being referred to our tertiary care units. It is also possible that we have included more patients with late onset RA into our cohort as PMR and elderly onset RA can be difficult to discriminate. A proportion of patients with late onset RA have been found to present with PMR features at disease onset with prevalent involvement of the girdles, high ESR levels, and good response to low-dose steroid treatment [7] . These patients were typically seronegative for RF. A Japanese group has attempted to refine criteria for detection of PMR with higher sensitivity and specificity among their elderly subjects if the patient fulfills all of the following: persistent bilateral muscular pain for >2 weeks involving ≥2 of the neck, shoulder girdle, upper arms, pelvis girdle, and thighs; normal muscle enzyme level; ESR >40 mm/h; and absence of hand joints involvement [16] . However, the sensitivity of diagnosing PMR using such criteria on our cohort was 70% only. We have explored the role of RF and anti-CCP antibodies as predictive serological markers for subsequent evolvement into RA. We found a high frequency of 67% of RF in those PMR patients who developed into RA, comparable to that observed in elderly onset RA [13] . RF is still present in 9.4% of those patients who had not evolved into RA and is likely related to the increased prevalence of RF in the aged. Indeed, 10-15% of subjects older than 65 years of age have been reported to have positive RF [12] . On the other hand, anti-CCP antibodies were not present in 93.8% of patients who had not evolved into RA during the time of observation suggesting a high specificity and a role to predict development of RA. In this study, only a marginally better sensitivity and positive predictive value of anti-CCP antibodies was demonstrated compared to RF which is probably related to the small sample size of our study. Anti-CCP antibodies have recently been found to be a specific serological marker for RA. The second-generation anti-CCP antibodies assay has comparable sensitivity as serum RF (80%) while demonstrating almost absolute specificity for the diagnosis of RA [17] . The production of anti-CCP antibodies has been found to be an early process in RA development, and their presence is predictive of the development of the disease [10] . Our result complemented the conclusions from a previous study which showed that anti-CCP antibodies were useful in the differential diagnosis of elderly onset RA and PMR [13] . In that study, 65% elderly onset RA patients showed increased serum titer for anti-CCP antibodies compared to none of the healthy subjects and PMR patients. Thus, anti-CCP antibodies may be a clinically useful marker to be tested at the onset of patients with PMR such that these patients can be followed up for the development of RA which requires different treatment modalities and carries different prognosis.
The average annual age-and sex-adjusted incidence of PMR aged 50 and older has been quoted as 54.8 per 100,000 population in the USA [18] . There has not been any large scale epidemiological study in the Chinese population. However, in the small number of patients we were able to retrieve from the clinical data analysis and reporting system involving databases in two large public hospitals over an 11-year-period, PMR does not appear to be a common condition in our locality. It remains possible that we are under diagnosing the condition given the lack of awareness at the levels of both patients and doctors and the absence of biomarker to aid clinical diagnosis. Education on the public, carers, and health care professionals is needed to raise awareness of this condition and the associated giant cell arteritis among different rheumatic problems encountered in the elderly so that they can be brought to medical attention earlier in their disease course. In conclusion, our study demonstrated that the spectrum of clinical features of PMR in Chinese patients is similar to that of the Caucasian counterpart. Larger prospective studies are warranted to delineate the role of clinical usefulness of anti-CCP antibodies in the early diagnosis and differentiation of PMR and RA.
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